Here’s Why Third Avenue Management Invested in Supernus Pharmaceuticals (SUPN)

Third Avenue Management, an investment management company, released its “Small-Cap Value Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. During the second quarter, the fund declined 8.03% compared to a decline of 15.28% for its benchmark, the Russell 2000 Value Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Third Avenue Management discussed stocks like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the second quarter investor letter. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company. On September 21, 2022, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stock closed at $34.29 per share. One-month return of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was -2.59% and its shares gained 26.48% of their value over the last 52 weeks. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  has a market capitalization of $1.834 billion.

Here is what Third Avenue Management specifically said about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its Q2 2022 investor letter:

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will be highlighted in a future letter. Supernus was a notable healthcare investment as Fund Management has struggled to find investments in the Healthcare sector given stretched valuations. With the Healthcare sector down nearly 30% YTD, it provided an opportunity to add a healthcare company to the Fund.”

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 19 hedge fund portfolios held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) at the end of the second quarter which was 17 in the previous quarter.

We discussed Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in another article and shared WertArt Capital’s views on the company. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Disclosure: None. This article is originally published at Insider Monkey.